Cheng Chi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Cheng Chi has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Baohong Hu
Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China
1 shared publicationFengcai DU
The First Clinical College of DaLian Medical University, Dalian, P.R. China
1 shared publicationHongjin Chu
The Central Laboratory, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China
1 shared publicationJ. Liu
Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication- Jian Chen
Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China
1 shared publication Peiwen Lian
The Central Laboratory, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China
1 shared publication
Latest Publications
- Open Access
- 20 October 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 177 (4) , e159
Image Gallery: Porokeratosis under the dermoscopic furrow ink test and ultraviolet light
- 20 October 2017
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 177 (4) , e159
Open AccessImage Gallery: Porokeratosis under the dermoscopic furrow ink test and ultraviolet light
- Open Access
- 20 July 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (8) , 4587-4591
Better Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion
Background/Aim: To evaluate the clinical efficiency of tumor-infiltrating lymphocytes (TILs) compared to cisplatin for malignant pleural effusion and ascites through intrapleural and intraperitoneal infusion. Patients and Methods: Thirteen patients with malignant pleural effusion and ascites were divided into a TIL-treated group and a cisplatin-treated group. Patients were given TILs or cisplatin, through intrapleural and intraperitoneal infusion respectively, after drainage of the malignant serous effusion by thoracentesis or abdominocentesis. Results: The overall response rate and disease control rate of the TIL-treated group (33.33% and 83.33%) were higher than that of the cisplatin-treated group (28.57% and 71.43%). The progression-free survival for the TIL-treated group was significantly longer (p=0.002) and better than that of the cisplatin-treated group (66.67% vs. 28.57%). Quality of life apparently improved in the TIL-treated group and was clearly higher than that in the cisplatin-treated group. Conclusion: The use of TILs has a better clinical efficiency for malignant pleural effusion and ascites than cisplatin through intrapleural and intraperitoneal infusion without severe adverse effects.
- 20 July 2017
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 37 (8) , 4587-4591
Open AccessBetter Clinical Efficiency of TILs for Malignant Pleural Effusion and Ascites than Cisplatin Through Intrapleural and Intraperitoneal Infusion
Background/Aim: To evaluate the clinical efficiency of tumor-infiltrating lymphocytes (TILs) compared to cisplatin for malignant pleural effusion and ascites through intrapleural and intraperitoneal infusion. Patients and Methods: Thirteen patients with malignant pleural effusion and ascites were divided into a TIL-treated group and a cisplatin-treated group. Patients were given TILs or cisplatin, through intrapleural and intraperitoneal infusion respectively, after drainage of the malignant serous effusion by thoracentesis or abdominocentesis. Results: The overall response rate and disease control rate of the TIL-treated group (33.33% and 83.33%) were higher than that of the cisplatin-treated group (28.57% and 71.43%). The progression-free survival for the TIL-treated group was significantly longer (p=0.002) and better than that of the cisplatin-treated group (66.67% vs. 28.57%). Quality of life apparently improved in the TIL-treated group and was clearly higher than that in the cisplatin-treated group. Conclusion: The use of TILs has a better clinical efficiency for malignant pleural effusion and ascites than cisplatin through intrapleural and intraperitoneal infusion without severe adverse effects.